Sort
82,697 grants matching “vaccine development”
Application of Flow Cytometry to Cell Biology
$1,337,746Susan Sharrow · Division Of Basic Sciences - Nci · ZIC · FY2012 · CA
Antibody immunotherapeutics for biodefense against Lassa virus
$1,337,737Robert F Garry · Tulane University Of Louisiana · R01 · FY2013 · AI
Dendritic Cell Biology and Therapy
$1,337,725University Of Pittsburgh At Pittsburgh · P01 · FY2005 · CA
MYCOBACTERIUM TUBERCULOSIS (MTB) QUALITY ASSESSMENT PROGRAM (TBQA)
$1,337,240Jeanette Coffin · Midwest Research Institute · N01 · FY2017 · AI
Miami HIV/AIDS Clinical Therapeutic and Vaccine Trial Unit
$1,337,183Margaret A Fischl · University Of Miami School Of Medicine · U01 · FY2010 · AI
Clinical Development of Chimp Adenovirus Vectors
$1,337,138Hildegund C. J. Ertl · Wistar Institute · U19 · FY2008 · AI
Dendritic Cell Biology and Therapy
$1,337,018Olivera J Finn · University Of Pittsburgh At Pittsburgh · P01 · FY2007 · CA
Neonatal Immunity to novel TF SHIVs
$1,336,670Wilton B Williams · Duke University · R01 · FY2021 · AI
PEDIATRIC ACTG - ACTU
$1,336,540University Of Miami School Of Medicine · U01 · FY2000 · AI
Immunity to Pneumonic Tularemia
$1,336,107Catharine Bosio · National Institute Of Allergy And Infectious Diseases · Z01 · FY2008 · AI
Microfabrication for Biomedical Research
$1,335,983Nicole Y Morgan · National Institute Of Biomedical Imaging And Bioengineering · ZIC · FY2023 · EB
Stimulant Pharmacotherapy: Noradrenergic Targets
$1,335,907Thomas Richard Kosten · Baylor College Of Medicine · P50 · FY2010 · DA
Role of inflammation, innate resistance, and immunity in carcinogenesis.
$1,335,686Giorgio Trinchieri · Division Of Basic Sciences - Nci · ZIA · FY2011 · CA
CoVPN Cross-Protocol Analyses
$1,334,886Peter B. Gilbert · Fred Hutchinson Cancer Research Center · UM1 · FY2022 · AI
New Approaches To Passive Immunoprophylaxis
$1,334,542Robert H. Purcell · National Institute Of Allergy And Infectious Diseases · ZIA · FY2011 · AI
1/2 CCNY-MSK Partnership for Cancer Research, Education and Community Outreach
$1,334,500Karen Hubbard · City College Of New York · U54 · FY2024 · CA
SAN FRANCISCO HIV VACCINE CLINICAL TRAILS UNIT
$1,334,433Public Health Foundation Enterprises · U01 · FY2002 · AI
PHARMACOKINETIC AND PHARMACODYNAMIC STUDIES FOR MEDICATIONS DEVELOPMENT. POP: 9/20/2017-9/19/2022. N01DA-17-8935.
$1,334,220Elizabeth Polvent · · N01 · FY2019 · DA
Immune correlates of protection
$1,334,187Richard A Koup · National Institute Of Allergy And Infectious Diseases · ZIA · FY2018 · AI
HIV/SIV Replication In Vivo
$1,334,187Richard A Koup · National Institute Of Allergy And Infectious Diseases · ZIA · FY2018 · AI
Paramyxoviruses as Vaccine Vectors Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
$1,334,000Ursula Buchholz · National Institute Of Allergy And Infectious Diseases · ZIA · FY2025 · AI
Protein-mediated membrane remodeling
$1,333,804Leonid V. Chernomordik · Eunice Kennedy Shriver National Institute Of Child Health & Human Development · ZIA · FY2012 · HD
HIVRAD: Structural approaches to vaccine development
$1,333,743Dana-Farber Cancer Institute · P01 · FY2003 · AI
Primate Core
$1,333,524Hans-Peter Kiem · University Of Southern California · U19 · FY2023 · HL
Immunotherapeutics for Treatment of Flavivirus Infection
$1,333,412Erol Fikrig · Yale University · U01 · FY2010 · AI